Biogen Inc. (BVMF:BIIB34)

Market Cap	140.62B
Revenue (ttm)	53.65B
Net Income (ttm)	8.57B
Shares Out	n/a
EPS (ttm)	58.49
PE Ratio	16.40
Forward PE	13.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3
Average Volume	48
Open	161.44
Previous Close	159.84
Day's Range	161.44 - 161.60
52-Week Range	110.07 - 165.60
Beta	0.15
RSI	70.10
Earnings Date	Feb 12, 2026

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1978
• Employees: 7,605
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: BIIB34

Financial Performance

In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.

Financial numbers in USD